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Introduction
Pediatric chronic nonbacterial osteomyelitis (CNO) is a
sterile inflammatory bone disorder in which innate and
adaptive immunity dysfunction involved. Unifocal and
multifocal disease courses are known. The modern
treatment modalities include non-steroid anti-inflamma-
tory drugs (NSAIDs), steroids, sulfasalazine (SSZ), meth-
otrexate (MTX), bisphosphonates and biologic drugs -
TNFa and IL1b-antagonists, with limited data.
Objectives
The aim of our study was to assess children with CNO
and to evaluate efficacy of treatment modalities.
Methods
Our cohort of CNO patients included 22 children, 8 boys
and 14 girls. Monofocal disease course was in 9/22
children (40.9), multifocal in 13/22 (59.1) with mean 6 foci
per patient. Histological confirmation was made in 13/22.
Repeated MRI, CT and bone scintigraphy was performed
in all patients. 3 patients have family history of autoimmu-
nity (1 Crohn’s disease, 1 - psoriasis, 1 - ankylosing. 16
patients (72,7%) had comorbid autoimmune diseases
(different types of JIA): 5 had monoarthritis, 1 arthritis
with uveitis, 1 - psoriatic arthritis, 1 - polyarthritis PF neg,
6 had enthesitis-related arthritis (3 had ankylosing spondy-
loarthritis) and 1 had Crohn’s disease. Spine involvement
was in 5/22 (22.7). Onset age was 8.5 (6.3; 10.5) years, the
right diagnosis delay was 3.6 (1.7; 9.5) months.
Results
Fever at onset, high painVAS and parental VAS scores
highly correlated with risk of relapse disease course.
Treatment: effectiveness of NSAID only 3/10 (30%), SSZ
- 1/5 (20%), corticosteroids - 0/3 (short-term effect
only), MTX - 4/7 (57.1%), pamidronate (PAM) with par-
tial response 2/12 (16.7%) and with complete response -
10/12 (83.3%). Biologics - adalimumab and etanercept
were effective in 3/4 (75%) patients, who fail to NSAID,
MTX, PAM and SSZ. During disease course treatment
lead to decreasing sings of disease activity, such as: par-
ental VAS (p = 0.015), pain VAS (p = 0.026), MDVAS
(p = 0.026), CRP (p = 0.0008), WBC (p = 0.006), ESR
(p = 0.00024), PLT (0.014). The main effectiveness
belonged to PAM (p = 0.003) and biologics (p = 0.07) in
decreasing of pain VAS (-100% and -80%), parental VAS
(-92% and -74%) and MD VAS (-93% and -70%, respec-
tively). We calculated the cumulative probability of sur-
vival (event of interest: CNO flare) in the entire patient
sample, depending the kind of treatment (PAM, MTX
and NSAID) obtained by the Kaplan-Meier method. Sig-
nificant difference was proved comparing 3 therapeutical
branches (p = 0.028). MTX treatment was effective (p =
0.04), as well as PAM (p = 0.01) than NSAID. Only flu-
like syndrome during PAM treatment was in 10/12
(83.3%). No any others side effects were reported. All
patients who had flu-like syndrome on first infusion had
complete response to PAM, vice verse patients, who had
no such complication had only partial response to this
treatment.
Conclusion
CNO is a group of chronic inflammatory conditions
associated with different rheumatic diseases. The most
effective treatment modalities were PAM, biologics and
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MTX. PAM was safety and can reach the rapid response
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